BeyondSpring (BYSI) Change in Account Payables (2016 - 2026)
BeyondSpring (BYSI) posted Change in Account Payables of $4.2 million for Q1 2026, up 5438.67% sequentially from $75000.0 in Q4 2025, and up 17960.87% YoY from N/an in Q1 2025.
BeyondSpring (BYSI) Change in Account Payables (2016 - 2026) Analysis & Trends
BeyondSpring has reported Change in Account Payables for 9 years, with the latest figure at $4.2 million in Q1 2026.
- Quarterly Change in Account Payables rose 17960.87% year-over-year to $4.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (up 631.45% YoY) and the FY2025 annual result came in at -$76000.0, up 87.48% from the prior year.
- Change in Account Payables grew to $4.2 million in Q1 2026 per BYSI's latest filing, from $75000.0 in the prior quarter.
- Over five years, Change in Account Payables peaked at $4.2 million in Q1 2026 and troughed at -$1.4 million in Q3 2024.
- A 3-year average of $385666.7 and a median of $75000.0 in 2025 frame the typical range for Change in Account Payables.
- The sharpest annual moves came in 2025 and 2026: Change in Account Payables tumbled 151.13% in 2025, then soared 17960.87% in 2026.
- Over 3 years, Change in Account Payables stood at $38000.0 in 2024, then soared by 97.37% to $75000.0 in 2025, then surged by 5438.67% to $4.2 million in 2026.
- According to Business Quant data, Change in Account Payables over the past three periods registered $4.2 million, $75000.0, and $98000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -66.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -8.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 37.53 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | BeyondSpring | 29.85 Mn | 29.85 Mn | - | 887,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 887,000.00 |
| Jun 30, 2026 | 887,000.00 |
| Mar 31, 2026 | 4.15 Mn |
| Mar 31, 2026 | 4.15 Mn |
| Dec 31, 2025 | 75,000.00 |
| Dec 31, 2025 | 75,000.00 |
| Sep 30, 2025 | 98,000.00 |
| Sep 30, 2025 | 98,000.00 |
| Jun 30, 2025 | -272,000.00 |
| Jun 30, 2025 | -272,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Mar 31, 2025 | 23,000.00 |
| Dec 31, 2024 | 38,000.00 |
| Dec 31, 2024 | 38,000.00 |
| Sep 30, 2024 | -1.36 Mn |
| Sep 30, 2024 | -1.36 Mn |
| Jun 30, 2024 | 532,000.00 |
| Jun 30, 2024 | 532,000.00 |
| Mar 31, 2024 | 179,000.00 |
| Mar 31, 2024 | 179,000.00 |